



Eosinophilic complications during dupilumab therapy for type 2 diseases




35

- Pubmed
- EMBASE
- Scopus
- Web of Science



53

of ~1 million dupilumab recipients



Most common complications




24

EGPA



15

Eosinophilic pneumonia



6


Hypereosinophilic syndrome




Complications developed after median 9 weeks



Typically managed with systemic corticosteroids



Median eosinophilic count at diagnosis: 6.38×10^9 cells/L



Discontinued dupilumab therapy

Complications

-  • Extremely rare
-  • Usually emerge in first months of treatment

→ The present findings challenge the need for prolonged BEC monitoring

→ No patterns / predictors identified

